Investment analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.
InspireMD Stock Performance
NSPR stock opened at $2.45 on Friday. The company has a fifty day moving average price of $2.48 and a 200-day moving average price of $2.52. The company has a market capitalization of $61.08 million, a P/E ratio of -3.23 and a beta of 0.96. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.85.
InspireMD (NYSE:NSPR – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The firm had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter last year, the company earned ($0.53) earnings per share. As a group, sell-side analysts forecast that InspireMD will post -0.82 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About InspireMD
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Further Reading
- Five stocks we like better than InspireMD
- What Makes a Stock a Good Dividend Stock?
- Top 3 Defense Stocks That Should Be on Your Radar
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.